Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma

참고문헌 (10)

1. Cho Y, "Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma : an Asian perspective comparison", Clin Mol Hepatol, 29, pp.252~262 (2023)
2. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
3. Kim DY, "Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region", Clin Mol Hepatol, 29, pp.277~292 (2023)
4. Park JG, "Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC", Hepatology (2024)[DOI]
5. Sogbe M, "Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment", Clin Mol Hepatol, 30, pp.177~190 (2024)
6. Han JW, "Predicting outcomes of atezolizumab and bevacizumab treatment in patients with hepatocellular carcinoma", Int J Mol Sci, 24, pp.11799~ (2023)
7. Hwang SH, "Radiologic features of hepatocellular carcinoma related to prognosis", J Liver Cancer, 23, pp.143~156 (2023)
8. Song BG, "Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma", Gut Liver, 18, pp.709~718 (2024)
9. Scheiner B, "Prognosis of patients with hepatocellular carcinoma treated with immunotherapy : development and validation of the CRAFITY score", J Hepatol, 76, pp.353~363 (2022)
10. McMillan DC, "The systemic inflammation-based Glasgow Prognostic Score : a decade of experience in patients with cancer", Cancer Treat Rev, 39, pp.534~540 (2013)

관련 논문AI추천